MK-677 (Ibutamoren) and Trazodone Interaction: Safety, Risks, and Clinical Guidance

What MK-677 and Trazodone Each Do in the Body

MK-677 (ibutamoren mesylate) is a non-peptide ghrelin receptor agonist that stimulates pulsatile growth hormone (GH) release from the anterior pituitary without suppressing endogenous GH secretion patterns. A 1998 study published in the Journal of Clinical Endocrinology & Metabolism (N=32) demonstrated that 25 mg/day of MK-677 increased IGF-1 levels by approximately 40% over 12 months in healthy older adults 1. The compound also activates appetite-signaling pathways through ghrelin mimicry, which can increase caloric intake by 300 to 500 kcal/day in some users.

Trazodone is a triazolopyridine-derivative antidepressant classified as a serotonin antagonist and reuptake inhibitor (SARI). At antidepressant doses (150 to 400 mg/day), it blocks 5-HT2A receptors and weakly inhibits serotonin reuptake. At lower doses (25 to 100 mg), its strong histamine H1-receptor antagonism and alpha-1 adrenergic blockade produce the sedation that makes it one of the most widely prescribed off-label sleep aids in the United States. The FDA-approved label for trazodone lists somnolence, dizziness, and orthostatic hypotension among its most common adverse effects [2].

Both compounds independently cause drowsiness. That overlap forms the core safety concern.

Pharmacokinetic Interaction: CYP3A4 and Clearance

Trazodone is primarily metabolized by CYP3A4, with a secondary contribution from CYP2D6, to its active metabolite meta-chlorophenylpiperazine (mCPP) 3. Strong CYP3A4 inhibitors such as ritonavir and ketoconazole can raise trazodone plasma concentrations two- to fourfold, per the FDA label [2].

MK-677's metabolic pathway is less thoroughly characterized in published literature because the compound never completed FDA approval. Preclinical and phase-II data from Merck suggest hepatic metabolism with CYP3A4 involvement 4. If both drugs compete for CYP3A4 active sites, one or both could accumulate to higher-than-expected plasma concentrations. The clinical significance of this competition remains unquantified. No published pharmacokinetic interaction study exists for this pair.

A reasonable clinical assumption: co-administration could modestly slow trazodone clearance, increasing the risk of dose-dependent adverse effects like prolonged sedation and orthostatic hypotension. Patients on concomitant CYP3A4 inhibitors (e.g., clarithromycin, grapefruit juice in large quantities) face compounded risk.

Pharmacodynamic Interaction: Sedation, Glucose, and Appetite

The pharmacodynamic overlap is more clinically pressing than the pharmacokinetic one.

Sedation. MK-677 users frequently report increased sleepiness, particularly in the first two to four weeks of use. Trazodone's sedative effect peaks one to two hours after an oral dose and persists six to eight hours at typical sleep-aid doses. Combining both agents, especially when taken in the evening, could produce next-morning hangover sedation that impairs driving and occupational performance. The American Academy of Sleep Medicine's 2017 clinical practice guideline already cautions against stacking sedating agents in patients with insomnia [5].

Glucose metabolism. MK-677 increases fasting blood glucose. In a two-month trial of MK-677 25 mg/day in older adults (N=65), fasting glucose rose by an average of 0.3 mmol/L and insulin resistance (HOMA-IR) worsened 6. Trazodone, by contrast, has a relatively neutral or mildly favorable glucose profile compared to other psychotropics. The interaction risk here is unidirectional: MK-677 worsens glycemic control regardless of trazodone co-use, but clinicians managing both drugs need to track glucose more aggressively than they would with trazodone alone.

Appetite and weight. MK-677's ghrelin-mimetic action increases hunger. Trazodone can also cause weight gain through histamine H1 blockade, though to a lesser degree than mirtazapine. The combination may produce additive appetite stimulation in patients already struggling with weight management.

Cardiac rhythm. Trazodone has been associated with QTc prolongation, particularly at doses above 300 mg/day or in patients with pre-existing cardiac conditions 7. MK-677 has not demonstrated QTc effects in published human data, but the lack of rigorous post-marketing surveillance (because it was never approved) means this cannot be ruled out. Baseline and periodic ECG monitoring is reasonable.

Who Is Most at Risk From This Combination

Not every patient faces equal hazard. Risk concentrates in specific populations.

Older adults metabolize both drugs more slowly due to reduced hepatic CYP3A4 activity and lower renal clearance. A 70-year-old on trazodone 50 mg and MK-677 25 mg will carry higher trough plasma levels of both compounds than a 30-year-old on identical doses. The sedation-related fall risk in this group is a genuine patient-safety concern. Hip fracture incidence already rises with sedating medication use in adults over 65, as documented in a meta-analysis of 23 observational studies 8.

Patients with pre-diabetes or type 2 diabetes should approach MK-677 with particular caution. Adding a GH secretagogue to a metabolic profile already marked by insulin resistance can push HbA1c above treatment targets. Trazodone does not worsen this, but it does not protect against it either.

Individuals with obstructive sleep apnea (OSA) face compounded sedation risk. Both drugs depress arousal thresholds, and MK-677's association with fluid retention could worsen upper-airway soft-tissue edema.

Monitoring Protocol When Using Both Agents

A structured monitoring approach reduces the risks of co-administration.

Before starting the combination:

• Fasting glucose and HbA1c (baseline metabolic status)
• IGF-1 level (to track GH-axis response to MK-677)
• 12-lead ECG if the patient is on trazodone doses above 150 mg/day or has cardiac risk factors
• Epworth Sleepiness Scale (ESS) or equivalent subjective sleepiness assessment
• Body weight and BMI

At 4 weeks:

• Repeat fasting glucose
• Reassess daytime somnolence (ESS score)
• Review sleep quality. If the patient reports excessive morning grogginess, consider separating dosing times or reducing MK-677 to 10 to 15 mg
• Check for peripheral edema (an MK-677 effect mediated by GH-driven fluid retention)

At 12 weeks and quarterly thereafter:

• Fasting glucose, HbA1c, IGF-1
• Body weight trend
• ECG if trazodone dose has been escalated
• Clinical reassessment of whether MK-677 continues to serve the patient's goals

Dr. Peter Attia has noted publicly that "any compound that raises IGF-1 chronically deserves the same metabolic surveillance you would give exogenous growth hormone." While MK-677 is not exogenous GH, its sustained IGF-1 elevation produces overlapping metabolic consequences.

Dose-Adjustment Considerations

No formal dosing guideline exists for this combination. The following reflects pharmacologic reasoning, not randomized trial data.

Start MK-677 at the lower end of the commonly reported range (10 mg/day rather than 25 mg) when adding it to existing trazodone therapy. This allows assessment of sedation burden before dose escalation. Trazodone doses for insomnia (25 to 100 mg) carry less interaction risk than antidepressant doses (150 to 400 mg) simply because lower doses produce less CYP3A4 substrate load and less histaminergic sedation.

If a patient requires trazodone at antidepressant-range doses and also uses MK-677, consider spacing the two by at least four hours. Taking MK-677 in the morning and trazodone at bedtime separates peak plasma concentrations and reduces the window of maximal sedation overlap. This strategy is theoretical but aligns with general polypharmacy principles endorsed by the American Geriatrics Society Beers Criteria for managing CNS-active drug combinations [9].

Patients who develop fasting glucose values above 5.6 mmol/L (100 mg/dL) after starting MK-677 should have their MK-677 dose reduced or discontinued before adjusting trazodone, since trazodone is not the glucose-raising agent.

Why No Direct Interaction Study Exists

MK-677 (ibutamoren) was developed by Merck Research Laboratories in the 1990s. It reached phase II trials for growth hormone deficiency, sarcopenia, and hip-fracture recovery but was never submitted for FDA approval. A two-year trial in elderly adults (N=292) failed to show significant improvement in functional outcomes despite sustained GH and IGF-1 increases 10. Merck discontinued development.

Because MK-677 never received regulatory approval, no manufacturer was required to conduct the standard battery of drug-drug interaction studies that the FDA's 2020 guidance on clinical drug interaction studies mandates for new molecular entities [11]. The compound now circulates through research-chemical suppliers and is classified by the World Anti-Doping Agency as a prohibited substance (category S2: peptide hormones, growth factors, and related substances).

This regulatory gap means clinicians must reason from first principles (mechanism, metabolism, shared adverse-effect profiles) rather than from dedicated interaction data.

Trazodone Interactions With Other GH-Axis Agents

Trazodone's interaction profile with GH-axis compounds is not unique to MK-677. Patients on sermorelin, tesamorelin, or even exogenous GH face a similar sedation-overlap concern, though those peptides are typically administered subcutaneously and have different pharmacokinetic profiles. The CYP3A4 competition is more specific to MK-677 because oral bioavailability and hepatic first-pass metabolism create the opportunity for enzyme-level competition that injectable peptides largely bypass.

For patients who need both GH-axis stimulation and an antidepressant or sleep aid, alternatives to trazodone with less CYP3A4 involvement include low-dose doxepin (3 to 6 mg, FDA-approved for insomnia as Silenor) or suvorexant (a dual orexin receptor antagonist metabolized by CYP3A4 but with well-characterized interaction data). Switching the GH secretagogue to an injectable GHRH analog removes the oral CYP3A4 competition entirely.

Patient Counseling Points

Patients combining these two agents should receive specific, actionable guidance:

Do not drive or operate heavy machinery until you have taken both drugs together for at least seven days and confirmed that daytime alertness is not impaired. Report any episodes of morning confusion, unusual hunger spikes, swollen ankles, or numbness/tingling in the hands (a sign of GH-related carpal tunnel compression). Keep a log of fasting morning blood glucose at least twice weekly for the first month.

Alcohol amplifies the sedation risk of both MK-677 and trazodone. Even one standard drink can push the combined CNS-depressant effect past the threshold for safe function. The National Institute on Alcohol Abuse and Alcoholism advises against combining alcohol with any sedating medication [12].

Grapefruit and grapefruit juice inhibit intestinal CYP3A4, potentially raising plasma levels of both drugs. Patients should avoid grapefruit consumption or discuss the interaction with their prescriber.

If discontinuing MK-677, no taper is pharmacologically required. If discontinuing trazodone, gradual dose reduction over two to four weeks is standard practice to avoid discontinuation-related insomnia rebound.